Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age



Status:Not yet recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:13 - Any
Updated:4/6/2019
Start Date:June 1, 2019
End Date:May 31, 2023
Contact:Pierre Buekens, MD, PhD
Email:pbuekens@tulane.edu
Phone:5049888803

Use our guide to learn which trials are right for you!

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial

The investigators are proposing to perform a double-blinded, non-inferiority randomized
controlled trial comparing a short 30-day treatment with BZN 150mg/day (30d/150mg) vs. a
60-day treatment with BZN 300 mg/day (60d/300mg). The investigators will recruit not
previously treated T. cruzi seropositive women with a live birth during the postpartum period
in Argentina, randomize them at six months postpartum, and follow them up with the following
specific aims:

Specific Aim 1: To measure the effect of BZN 30d/150mg compared to 60d/300mg preconceptional
treatment on parasitic load measured by the frequency of positive PCR (primary outcome) and
by real-time quantitative PCR (qPCR), immediately (Specific Aim 1a) and 10 months (Specific
Aim 1b) after treatment.

Hypothesis 1a: The frequency of positive PCR and the parasitic load measured by qPCR
immediately after BZN 30d/150mg will be non-inferior (Non Inferiority [NI] margin for PCR:
10% absolute difference) to BZN 60d/300mg.

Hypothesis 1b: The frequency of positive PCR and the parasitic load measured by qPCR 10
months after BZN 30d/150mg will be non-inferior (NI margin for PCR: 9% absolute difference)
to BZN 60d/300mg.

Specific Aim 2: To measure the frequency of serious adverse events leading to treatment
interruption of BZN 30d/150mg compared to 60d/300mg.

Hypothesis 2: The frequency of serious adverse events leading to treatment interruption will
be 50% lower with BZN 30d/150mg than with BZN 60d/300mg.

A 24-month recruitment period is planned in four hospitals with 23,436 deliveries in 2015 and
frequencies of T. cruzi seropositive women varying from 1.5% to 4.8%. The investigators are
planning to enroll 600 T. cruzi seropositive women.


Inclusion Criteria:

- Written informed consent from the mother.

- T. cruzi seropositivity confirmed by at least two positive tests.

- Live birth.

Exclusion Criteria:

- Women residing outside of the provinces of Chaco, Santiago del Estero, or Tucumán.

- Previous trypanocide treatment (BZN or nifurtimox).

- Female sterilization; no intention to use modern contraception methods during
treatment.

- Positive pregnancy test.

- History of severe alcohol abuse within two years; renal insufficiency.
We found this trial at
3
sites
Buenos Aires,
Principal Investigator: Fernando Althabe, MD, MSc
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Pierre Buekens, MD, PhD
Phone: 504-988-8803
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Edmund Capparelli, PharmD
Phone: 858-246-0009
?
mi
from
San Diego, CA
Click here to add this to my saved trials